Congress Asset Management Co. Has $55.97 Million Position in LeMaitre Vascular, Inc. $LMAT

Key Points

• Congress Asset Management Co. increased its position in LeMaitre Vascular by 4.6%, owning 673,968 shares valued at approximately $55.97 million as of the latest quarter.
• Insider transactions included CEO George W. Lemaitre selling 100,000 shares for over $9.35 million, indicating a 5.47% reduction in his ownership.
• LeMaitre Vascular reported Q2 2025 earnings of $0.60 per share, surpassing estimates, with revenue growing 15% compared to the previous year.

Congress Asset Management Co. lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 673,968 shares of the medical instruments supplier's stock after buying an additional 29,553 shares during the period. Congress Asset Management Co. owned about 2.98% of LeMaitre Vascular worth $55,973,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Avantax Advisory Services Inc. increased its holdings in LeMaitre Vascular by 1.5% during the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier's stock worth $1,261,000 after buying an additional 229 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of LeMaitre Vascular by 4.2% during the 1st quarter. HighTower Advisors LLC now owns 5,920 shares of the medical instruments supplier's stock worth $497,000 after purchasing an additional 237 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of LeMaitre Vascular by 1.1% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 22,282 shares of the medical instruments supplier's stock valued at $1,851,000 after purchasing an additional 245 shares during the period. Fifth Third Bancorp lifted its stake in LeMaitre Vascular by 2.3% in the 1st quarter. Fifth Third Bancorp now owns 10,903 shares of the medical instruments supplier's stock valued at $915,000 after purchasing an additional 246 shares during the last quarter. Finally, Cetera Investment Advisers grew its holdings in LeMaitre Vascular by 11.5% during the fourth quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock worth $254,000 after purchasing an additional 284 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director John A. Roush sold 6,561 shares of the firm's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares of the company's stock, valued at approximately $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 100,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer directly owned 1,727,003 shares of the company's stock, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is owned by insiders.

LeMaitre Vascular Stock Performance

LMAT opened at $84.66 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The firm has a market cap of $1.92 billion, a P/E ratio of 41.10, a price-to-earnings-growth ratio of 2.26 and a beta of 0.79. The business's fifty day moving average is $90.99 and its 200-day moving average is $86.11.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular's revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were given a dividend of $0.20 per share. The ex-dividend date was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular's payout ratio is currently 38.83%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on LMAT shares. Barrington Research reiterated an "outperform" rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a report on Tuesday. Cantor Fitzgerald upped their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.